Toxemia
toxemia
RECURRENCE, TOXEMIA
Treatment was initiated individually when an animal exhibited a PA assay result greater than the lower limit of quantification (1.5 ng/mL). Consequently, all animals exhibited PA in circulation before treatment when the results were analyzed. However, retrospectively it was determined that two animals treated with 30 U/kg ANTHRASIL were not toxemic prior to treatment and were therefore excluded from the survival analysis. At the time of treatment, circulating PA concentrations in various groups ranged from 1.61 ng/mL to 18.20 ng/mL (IGIV-treated), 1.90 ng/mL to 30.85 ng/mL (7.5 U/kg ANTHRASIL-treated),2.28 ng/mL to 150.33 ng/mL (15 U/kg ANTHRASIL-treated) or 1.92 ng/mL to 21.55 ng/mL (30 U/kg ANTHRASIL™-treated). Circulating PA levels were reduced to undetectable levels (< LOD) by ANTHRASIL in all but two animals (one each from the 7.5 U/kg and 15 U/kg ANTHRASIL-treated groups) when the first serum sample was assessed following treatment.The proportion of toxemic animals post-treatment was significantly greater in IGIV control group than in any other treatment group from 6 to 24 and from 24 to 36 hours post-treatment (p < 0.0001, p = 0.0065, respectively). Additionally, there was a discernible dose-dependent decrease in the proportion of toxemic animals from 6 h PoI onwards. A recurrence of toxemia was observed in some animals that received 7.5 and 15 U/kg ANTHRASIL (8 of 15 and 2 of 15 animals, respectively) (